{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Obi Y"],"pubmed_abstract":["<h4>Rationale & objective</h4>Patiromer is a potassium binder approved for the long-term management of hyperkalemia. Although patiromer use among patients with advanced chronic kidney disease (CKD) has been shown to reduce the discontinuation of renin-angiotensin-aldosterone system inhibition therapy, it remains unclear whether patiromer can improve clinical outcomes. The aim of this study was to examine the association of long-term patiromer use with clinical outcomes among hyperkalemic patients with CKD.<h4>Study design</h4>This was a longitudinal observational study.<h4>Setting & participants</h4>We evaluated a national cohort of 854,217 US Veterans who had at least 1 serum potassium measurement of ≥5.1 mEq/L and were treated at US Department of Veterans Affairs health care facilities b"],"journal":["Kidney medicine"],"pagination":["100757"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10772292"],"repository":["biostudies-literature"],"pubmed_title":["Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study."],"pmcid":["PMC10772292"],"pubmed_authors":["Goedecke P","Dashputre AA","Obi Y","Thomas F","Kovesdy CP"],"additional_accession":[]},"is_claimable":false,"name":"Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.","description":"<h4>Rationale & objective</h4>Patiromer is a potassium binder approved for the long-term management of hyperkalemia. Although patiromer use among patients with advanced chronic kidney disease (CKD) has been shown to reduce the discontinuation of renin-angiotensin-aldosterone system inhibition therapy, it remains unclear whether patiromer can improve clinical outcomes. The aim of this study was to examine the association of long-term patiromer use with clinical outcomes among hyperkalemic patients with CKD.<h4>Study design</h4>This was a longitudinal observational study.<h4>Setting & participants</h4>We evaluated a national cohort of 854,217 US Veterans who had at least 1 serum potassium measurement of ≥5.1 mEq/L and were treated at US Department of Veterans Affairs health care facilities b","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2025-04-04T21:29:03.078Z","creation":"2025-04-04T21:29:03.078Z"},"accession":"S-EPMC10772292","cross_references":{"pubmed":["38192434"],"doi":["10.1016/j.xkme.2023.100757"]}}